Provided by Tiger Trade Technology Pte. Ltd.

EyePoint

3.27
-0.1500-4.39%
Post-market: 3.300.0290+0.89%19:52 EDT
Volume:3.44M
Turnover:11.40M
Market Cap:281.91M
PE:-0.87
High:3.46
Open:3.42
Low:3.25
Close:3.42
52wk High:19.11
52wk Low:3.25
Shares:86.21M
Float Shares:60.67M
Volume Ratio:1.38
T/O Rate:5.67%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7642
EPS(LYR):-3.1667
ROE:-148.70%
ROA:-74.85%
PB:1.69
PE(LYR):-1.03

Loading ...

Rival Ocular Therapeutix Shares up 8%

THOMSON REUTERS
·
Aug 17

Morning Movers: EyePoint plummets following LUGANO trial results

TIPRANKS
·
Aug 17

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 17

EyePoint Tumbles After Experimental Eye Drug Misses Main Goal in Late-Stage Study

Reuters
·
Aug 17

EyePoint Eye Drug Misses Main Goal in Late-Stage Trial

Reuters
·
Aug 17

EyePoint Says Phase 3 Lugano Trial of Duravyu in Wet AMD Misses Primary Endpoint

Reuters
·
Aug 17

EyePoint - Primary Endpoint not Achieved in Full Dataset Due to Asymmetric Cohort

THOMSON REUTERS
·
Aug 17

EyePoint - Lucia Phase 3 Topline Data Expected Q4 2026; FDA Nda Submission Planned 1H 2027

THOMSON REUTERS
·
Aug 17

EyePoint Announces Topline Data from Lugano, the First of Two Pivotal Phase 3 Clinical Trials for Duravyu™ 2.7Mg in Wet Amd

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Achieves 42% Reduction in Treatment Burden vs Aflibercept

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Non-Inferior to Aflibercept in Ad Hoc Analysis Excluding 4% Asymmetric Cohort

THOMSON REUTERS
·
Aug 17

EyePoint - Duravyu Observed to be Safe and Well Tolerated with Repeat Dosing

THOMSON REUTERS
·
Aug 17

NASDAQ Trade Halt Halt News Pending at 06:55 Am

Reuters
·
Aug 17

EyePoint Grants Inducement Stock Options for 14,600 Shares at $14.75 Each

Reuters
·
Aug 15

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Aug 15

EyePoint (EYPT) Is Up 5.1% After Steep Q2 Revenue Drop And ESOP-Linked Share Offering Filing

Simply Wall St.
·
Aug 14

EyePoint Pharmaceuticals (EYPT) Gets a Buy from Mizuho Securities

TIPRANKS
·
Aug 12

EyePoint (EYPT) Completes Phase 3 Enrollment Early, Is The Stock Still Cheap?

Simply Wall St.
·
Aug 10

EyePoint is Maintained at Buy by Chardan Capital

Dow Jones
·
Aug 07

Smart Glass Tech Developer Research Frontiers' Q2 Fee Income Declines

Reuters
·
Aug 07